Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02744339
Other study ID # RIO-40400
Secondary ID 2014-003055-60
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2016
Est. completion date September 2020

Study information

Verified date November 2020
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to • Assess the pharmacodynamic profile of riociguat in subjects with symptomatic pulmonary hypertension and heart failure with preserved ejection fraction The secondary objectives of this study are to - Assess safety and tolerability of riociguat in this study population - Assess changes in dimensions of left and right ventricles and cardiac function parameters using cardiac magnetic resonance imaging


Recruitment information / eligibility

Status Completed
Enrollment 118
Est. completion date September 2020
Est. primary completion date August 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - 18 to <80 years of age at the time of informed consent (The lower age limit may be higher if legally required in participating countries.) - Male and female subjects with symptomatic PH and HF-PEF (group 2 / 2.2 of Dana Point classification(4) and WHO class II to IV) (Other groups of PH, especially HF-REF, PAH, CTEPH, must have been ruled out according to accepted diagnostic procedures and guidelines, see section 5.1.2 Exclusion criteria.) - PH-HF-PEF defined as: - LVEF =50%, diagnosed by echocardiography or left heart catheterization (LHC) within 30 days before randomization - PAPmean =25 mmHg at rest, measured by RHC - PAWP >15 mmHg at rest, measured by RHC - Optimized therapy for hypertension - The dose regimen of the background treatment must have been stable for >30 days before randomization. Diuretic therapy must have been stable for =1 week. - RHC results for the definite diagnosis of PH not older than 12 weeks at Visit 1. RHC must have been performed in the participating center under standardized conditions - CMRI must be performed at Visit 1 (baseline) or must not be older than 12 weeks with all parameters measured as listed in Section 7.3.3 - Women are eligible if not of childbearing potential, defined as: - Postmenopausal women (i.e. last menstrual bleeding at least 2 years before randomization) - Women with bilateral tubal ligation - Women with bilateral ovariectomy - Women with hysterectomy or, if of childbearing potential, women are eligible if - A serum pregnancy test is negative at the pre-study visit, and The woman uses a combination of condoms and a safe and highly effective contraception method (hormonal contraception with implants or combined oral contraceptives, certain intrauterine devices) for the entire duration of the study. - Able to understand and follow instructions and to participate in the study for its entire duration - Written informed consent Exclusion Criteria: - PH in groups other than group 2.2 according to Dana Point classification.(4) In particular, PAH, CTEPH, and HF-REF must have been ruled out according to accepted diagnostic procedures and guidelines. - Cardiac decompensation, with hospitalization or visit to the emergency department, =30 days before randomization - Left heart disease because of to ischemic heart disease or dilated cardiomyopathy - Resynchronization therapy at any time - Need for intravenous (IV) diuretics =30 days before randomization - Treatment with inotropes or IV vasodilators =30 days before randomization - Pre-treatment with endothelin receptor antagonists (ERAs), phosphodiesterase type 5 (PDE5) inhibitors, or prostanoids =30 days before randomization, or with nitrates =7 days before randomization - Subjects who medically require treatment with drugs that are not in line with the in- or exclusion criteria of this study or that are prohibited concomitant medications (see section 6.9) for this study - Bronchial asthma or chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) <60% of predicted - Restrictive lung disease with total lung capacity (TLC) <60% of predicted - Subjects on oxygen therapy - Severe congenital abnormalities of the lung, thorax, or diaphragm - Clinically relevant hepatic dysfunction shown by: - Aspartate aminotransferase (AST) =3 times the upper limit of normal (ULN) or - Child Pugh stage B and C in cirrhotic subjects - Severe renal impairment (glomerular filtration rate [GFR] <30mL/min/1.73 m2 calculated by the Modification of Diet in Renal Disease [MDRD] formula) - Uncontrolled arterial hypertension (SBP >180 mmHg or diastolic blood pressure [DBP] >110 mmHg) - SBP <110 mmHg at baseline - Myocardial disease, such as ischemic or dilative infiltrative myocardial disease (i.e. amyloidosis, hypertrophic cardiomyopathy) - Severe aortic or mitral stenosis, or any such stenosis with indication for surgery - Coronary artery disease with angina of Canadian Cardiovascular Society (CCS) class III or IV or requiring nitrates, unstable angina, or acute myocardial infarction <90 days before randomization - Reperfusion procedure (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]) <90 days before randomization, or <21 days in case of a negative stress test effect after PCI - Stroke with persistent neurological deficit - Subjects positive for human immunodeficiency virus (HIV) - Resting HR while awake of <50 beats per minute (BPM) or >105 BPM (in case of atrial fibrillation >110 BPM) - Participation in another clinical study <90 days before randomization - Subjects with a medical disorder, condition, or history thereof that in the opinion of the investigator would impair the subject's ability to participate or complete the 26-week study - Subjects with underlying medical disorders with an anticipated life expectancy below 2 years because of a non-cardiac disease (e.g. active cancer disease with localized and / or metastasized tumor mass) - Subjects with a history of multiple drug allergies - Subjects with hypersensitivity to the investigational drug or any of the excipients - Previous assignment to treatment during this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Riociguat
Adempas up-titrated to max. 1.5mg TID
Placebo
Placebo sham-titrated TID

Locations

Country Name City State
Austria Medical University of Vienna Vienna

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Other Change from baseline in T1-mapping parameters by CMR Change from baseline in native T1 times of the left ventricular myocardium Baseline and 26 weeks after study drug treatment
Other Change from baseline in T1-mapping parameters by CMR Change from baseline in extracellular volume of the left ventricular myocardium Baseline and 26 weeks after study drug treatment
Other Change from baseline in echocardiography parameters Change from baseline in left ventricular end-systolic volume by echocardiography Baseline and 26 weeks after study drug treatment
Other Change from baseline in echocardiography parameters Change from baseline in left ventricular end-diastolic volume by echocardiography Baseline and 26 weeks after study drug treatment
Other Change from baseline in echocardiography parameters Change from baseline in tricuspid annular plan systolic excursion by echocardiography Baseline and 26 weeks after study drug treatment
Other Change from baseline in echocardiography parameters Change from baseline in pressure gradient of tricuspid valve by echocardiography Baseline and 26 weeks after study drug treatment
Other Change from baseline in echocardiography parameters Change from baseline in diameter of inferior vena cava by echocardiography Baseline and 26 weeks after study drug treatment
Other Change from baseline in echocardiography parameters Change from baseline in respiratory collapsibility of inferior vena cava by echocardiography Baseline and 26 weeks after study drug treatment
Other Change from baseline in echocardiography parameters Change from baseline in mitral peak velocity of early (E) filling by echocardiography Baseline and 26 weeks after study drug treatment
Other Change from baseline in echocardiography parameters Change from baseline in mitral peak velocity of late (A) filling by echocardiography Baseline and 26 weeks after study drug treatment
Other Change from baseline in echocardiography parameters Change from baseline in E-wave deceleration time by echocardiography Baseline and 26 weeks after study drug treatment
Other Change from baseline in echocardiography parameters Change from baseline in left ventricular ejection fraction by echocardiography Baseline and 26 weeks after study drug treatment
Other Change from baseline in echocardiography parameters Change from baseline in estimate of mean right atrial pressure by echocardiography Baseline and 26 weeks after study drug treatment
Other Change from baseline in echocardiography parameters Change from baseline in systolic pulmonary artery pressure by echocardiography Baseline and 26 weeks after study drug treatment
Other Change from baseline in echocardiography parameters Change from baseline in E/A ratio by echocardiography Baseline and 26 weeks after study drug treatment
Other Change from baseline in exercise capacity: 6-minute walk distance Baseline and 26 weeks after study drug treatment
Other Change from baseline in exercise capacity: Borg CR 10 scale Baseline and 26 weeks after study drug treatment
Other Change from baseline in quality of life scores: EQ-5D Baseline and 26 weeks after study drug treatment
Other Change from baseline in quality of life scores: MLHF Baseline and 26 weeks after study drug treatment
Other Events of special interest Events of special interest considered for calculation of the combined endpoint "time to clinical worsening" Baseline and 26 weeks after study drug treatment
Other All-cause mortality Baseline and 26 weeks after study drug treatment
Other Composite endpoint Composite endpoint as defined by: time to death from cardiovascular causes or first hospitalization for a cardiovascular event, including acute or worsening heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia Baseline and 26 weeks after study drug treatment
Primary Change from baseline of cardiac output at rest, measured by right heart catheterization Change from baseline of cardiac output at rest, measured by right heart catheterization after 26 weeks of study drug treatment Baseline and 26 weeks after study drug treatment
Secondary Change from baseline in cardiac magnetic resonance imaging parameters Change from baseline in right ventricular ejection fraction by cardiac magnetic resonance imaging Baseline and 26 weeks after study drug treatment
Secondary Change from baseline in cardiac magnetic resonance imaging parameters Change from baseline in right ventricular volume by cardiac magnetic resonance imaging Baseline and 26 weeks after study drug treatment
Secondary Change from baseline in cardiac magnetic resonance imaging parameters Change from baseline in left atrial area by cardiac magnetic resonance imaging Baseline and 26 weeks after study drug treatment
Secondary Change from baseline in cardiac magnetic resonance imaging parameters Change from baseline in right atrial area by cardiac magnetic resonance imaging Baseline and 26 weeks after study drug treatment
Secondary Change from baseline in hemodynamic parameters other than cardiac output Change from baseline in pulmonary vascular resistance by right heart catheterization Baseline and 26 weeks after study drug treatment
Secondary Change from baseline in hemodynamic parameters other than cardiac output Change from baseline in pulmonary arterial wedge pressure by right heart catheterization Baseline and 26 weeks after study drug treatment
Secondary Change from baseline in hemodynamic parameters other than cardiac output Change from baseline in transpulmonary gradient by right heart catheterization Baseline and 26 weeks after study drug treatment
Secondary Change from baseline in hemodynamic parameters other than cardiac output Change from baseline in systemic vascular resistance by right heart catheterization Baseline and 26 weeks after study drug treatment
Secondary Change from baseline in WHO functional class Baseline and 26 weeks after study drug treatment
Secondary Change from baseline in biomarker levels Change from baseline in serum N-terminal prohormone B-type natriuretic peptide (NTproBNP) Baseline and 26 weeks after study drug treatment
See also
  Status Clinical Trial Phase
Completed NCT04095286 - Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants Phase 1
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT02191137 - Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) Phase 4
Completed NCT01959828 - Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery Phase 3
Withdrawn NCT01202045 - Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients N/A
Completed NCT00963001 - Effect of Food on the Pharmacokinetics of Oral Treprostinil Phase 1
Completed NCT01121458 - Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed Phase 4
Completed NCT00963027 - Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil Phase 1
Terminated NCT00825266 - Insulin Resistance in Pulmonary Arterial Hypertension Phase 4
Terminated NCT00384865 - A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension Phase 2
Active, not recruiting NCT03926572 - Acute Decompensation of Pulmonary Hypertension N/A
Completed NCT02826252 - Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20) N/A
Completed NCT02545465 - A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice N/A
Recruiting NCT04498299 - Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
Recruiting NCT02558582 - Effect of Exercise Training in Patients With Pulmonary Hypertension N/A
Active, not recruiting NCT02562235 - Riociguat in Children With Pulmonary Arterial Hypertension (PAH) Phase 3
Completed NCT02755298 - Chronic Clinical Effect of Acetazolamide Phase 2/Phase 3
Terminated NCT03043976 - Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension N/A
Completed NCT02576002 - Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension) N/A
Completed NCT01178073 - A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) Phase 3